We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000240
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 3, 2015
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont

Brief Summary:
The purpose of this study is to test combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 0 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement
Study Start Date : April 1999

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Drug use
  2. Retention
  3. Weeks abstinent
  4. Weeks continuous abstinence
  5. Overall treatment outcome
  6. Opioid dependence and psychiatric status

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   23 Years to 47 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000240

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Principal Investigator: Warren Bickel, Ph.D. University of Vermont

ClinicalTrials.gov Identifier: NCT00000240     History of Changes
Other Study ID Numbers: NIDA-06969-22
R01DA006969 ( U.S. NIH Grant/Contract )
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: June 3, 2015
Last Verified: April 1999

Additional relevant MeSH terms:
Opioid-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists